Avacta Group bullish on outlook

published 23 October 2012

Diagnostic technology provider Avacta Group posted a jump in 12-month revenues and predicted substantial progress over the coming financial year.

Group revenue grew 28% to £3.13m, but saw its operating loss widen to £1.64m, from £1.13m the year before.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Total revenue included £1.64m from Avacta Analytical assisted by the contribution of the 21 Optim installations and associated consumables and £1.49m from Avacta Animal Health.

However, the firm said it was disappointed in the delay to the commercial launch of its AX.1 point-of-care immunoassay system.

"The group has clear visibility on its short and long term commercial, technical and financial objectives and has a solid platform from which to achieve them," said Chairman Gwyn Humphreys.

"The board anticipates substantial progress across its operations in the current financial year."

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.